Medication Use and Risk of Microscopic Colitis: A Propensity-Matched Analysis of US Adults ≥ 50 Years (2014-2024).
Reinforcessuggested applicable standard· United European Gastroenterology (UEG) & European Microscopic Colitis Group (EMCG), "European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations" (Miehlke et al.), 2021, Recommendation 1.8
Decision at stakewithdrawal of implicated drugs in microscopic colitis
… First step is withdrawal of implicated drugs (PPIs, NSAIDs, SSRIs, and other suspected culprits such as statins/ARBs), but only for agents with a suspected chronological (temporal) relationship between drug introduction and onset of diarrhea, and only when discontinuation is clinically safe and an appropriate alternative exists, rather than reflexive class-wide withdrawal (the European UEG/EMCG guideline suggests considering withdrawal of any drug with such a temporal relationship, and notes PPI-switch data contradict a strict class effect), together with smoking-cessation counseling. …
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standard
Diagnose microscopic colitis on colonoscopy with biopsies from at least two colonic segments (proximal/ascending and distal/descending, ~3 biopsies per segment in separate jars, avoiding rectum-only sampling since it can miss >20% of cases), plus celiac serology (tTG-IgA) and an infectious workup before treatment. First step is withdrawal of implicated drugs (PPIs, NSAIDs, SSRIs, and other suspected culprits such as statins/ARBs), but only for agents with a suspected chronological (temporal) relationship between drug introduction and onset of diarrhea, and only when discontinuation is clinically safe and an appropriate alternative exists, rather than reflexive class-wide withdrawal (the European UEG/EMCG guideline suggests considering withdrawal of any drug with such a temporal relationship, and notes PPI-switch data contradict a strict class effect), together with smoking-cessation counseling. For symptomatic disease, AGA's guideline recommends budesonide 9 mg once daily for 6-8 weeks as induction, preferred over mesalamine (budesonide gave nearly double the remission rate in head-to-head RCTs); when budesonide is not feasible AGA suggests mesalamine, bismuth subsalicylate, or prednisone/prednisolone as second-line alternatives, the European UEG/EMCG guideline is stricter and recommends against mesalamine outright (not superior to placebo in trials). Maintenance uses budesonide tapered to the lowest effective dose (typically 4.5-6 mg/day) individualized to the patient, since roughly 80% relapse after stopping. Budesonide non-/partial responders should be evaluated for bile acid diarrhea (cholestyramine trial can reduce budesonide dependence), celiac disease, and SIBO before escalating refractory disease to thiopurines (azathioprine/6-MP) or biologics (anti-TNF, vedolizumab).